D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 42.33 CNY -1.17% Market Closed
Market Cap: 17.6B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Accounts Payable
ÂĄ108.9m
CAGR 3-Years
19%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accounts Payable
ÂĄ3.7B
CAGR 3-Years
20%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Accounts Payable
ÂĄ220.6m
CAGR 3-Years
-7%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accounts Payable
ÂĄ299.9m
CAGR 3-Years
39%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accounts Payable
ÂĄ16.3B
CAGR 3-Years
23%
CAGR 5-Years
42%
CAGR 10-Years
91%
Imeik Technology Development Co Ltd
SZSE:300896
Accounts Payable
ÂĄ44.7m
CAGR 3-Years
113%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
17.3B CNY
Industry
Biotechnology

In the heart of China's vibrant pharmaceutical landscape lies Dizal Jiangsu Pharmaceutical Co Ltd, a dynamic company at the forefront of innovative drug development. Founded as a joint venture with a vision to bridge unmet medical needs, Dizal focuses primarily on oncology and immunology. This firm thrives on its strong pipeline of next-generation therapies, nurtured by a robust research and development arm. Collaborating with global biotech entities, it leverages cutting-edge technologies and deep scientific acumen to create breakthrough biologic and small molecule drugs that hold the potential to transform patient outcomes. Dizal’s research hubs are bustling with expert scientists dedicated to translating scientific discoveries into tangible therapies, positioning the company as a significant player in the biopharmaceutical sector. Dizal makes its money through a well-orchestrated stream of activities emphasizing strategic partnerships, intellectual property licensing, and product sales. By forging alliances with industry giants for co-development and commercialization, the company ensures a wider reach and impactful roll-out of its products. Additionally, the progressive monetization strategy of awarding patents and licenses in conjunction with its proprietary compounds enables a steady revenue inflow. This symbiotic model not only empowers Dizal to fund further innovative research but also reinforces its stature within the competitive arena of drug development. As healthcare demands continuously evolve, Dizal’s revenue generation strategies remain agile, marrying scientific ingenuity with strategic foresight.

Intrinsic Value
29.34 CNY
Overvaluation 31%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Accounts Payable?
Accounts Payable
108.9m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Accounts Payable amounts to 108.9m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
14%

Over the last year, the Accounts Payable growth was -29%. The average annual Accounts Payable growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 19% over the past three years , 14% over the past five years .

Back to Top